This is to inform you that pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; the Board of Directors, at its meeting ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Globalspace Technologies' board, meeting on August 12, 2025, approved unaudited Q1 FY26 results (quarter ended June 30, 2025) on both standalone and consolidated basis. Standalone revenue fell to ₹475.87 lakh from ₹692.75 lakh a year ago, but the company swung to a profit of ₹12.07 lakh versus a loss of ₹262.71 lakh in Q1 FY25, largely because the prior-year quarter included a one-time loss of ₹275.65 lakh from the sale of its Kolkata office property. On a consolidated basis (including 51%-owned Innopharma Healthcare), revenue dipped to ₹877.86 lakh from ₹1,003.11 lakh, while net profit turned positive at ₹15.96 lakh versus a ₹257.46 lakh loss. The board also recommended re-appointing statutory auditor Bansi Lal Shah & Co. for a second 2-year term (FY26–FY28) and secretarial auditor AJP & Associates for 5 years (FY26–FY30), appointed Mr. Pulkit Chowdhary as an Additional Independent Director for 3 years, and fixed the 15th AGM for September 29, 2025.
The headline return to profitability is encouraging but largely reflects the absence of last year's one-time property-sale loss rather than strong operating recovery, since revenue actually declined YoY. Shareholders should watch upcoming quarters for a sustainable turnaround in topline and margin trends before drawing conclusions on the stock.